The project aims to improve methods for general practitioners to diagnose cancer, lowering waiting times and reducing the burden of referrals.
Several diagnostic industry organizations have inked a global commitment for collaborative action in the fight against AMR.
The collaborators will explore the use of cell-free DNA for preimplantation genetic testing.
As SpeeDx preps for the European launch of its STI tests, it will incorporate UgenTec's automated data analysis tool for PCR applications.
As part of the deal, Helomics will promote MDNA's Prostate Core Mitomic Test and its liquid biopsy Prostate Mitomic Test in select US markets.
The two companies have agreed to research the feasibility of using Celsee's CTC-based liquid biopsy technology to diagnose cancer in dogs.
The company has also announced a collaboration with Pfizer to develop a blood-based assay to identify critical-stage cardiometabolic conditions.
Roche, Eli Lilly, and others aim to elucidate differences in T2D patients in order to develop better diagnostic tools and new treatments.
Companion diagnostics developed under the deal will be based on RNAscope and immunohistochemistry technology.
The partners will evaluate new biomarkers that they both find, and will assess the possibility for a preterm birth prognostic panel.